References

2. Jaffe ES, Harris NL, Stein H et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 2001;


56. Derenne S, Monia B, Dean NM et al. **Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.** Blood 2002;100:194-9.


60. Quintanilla-Martinez L, Kremer M, Specht K et al. **Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.** American Journal of Pathology 2003;162:1449-61.


65. Lacey DL, Timms E, Tan HL et al. **Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.** Cell 1998;93:165-76.


77. Tian E. Elevated expression of WNT signaling antagonists DKK1 and FrzB by malignant plasma cells is strongly associated with lytic bone disease in myeloma. The Hematology Journal 2003;S19.


99. Richardson PG. A multi-center randomized phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 2002;100:104a (abstract).


References


References


References


193. Oakervee HE, McBride NC, Hemmaway C J. Thalidomide combined with vincristine, Adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. Blood 2002;100:402A.


197. Chung F, Palmer BD, Muller GW et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncology Research 2003;14:75-82.


References


References


References


